Clinical trials: Hepatitis C Virus (HCV)
HIV, Hepatitis C
Behavioral Science Aspects of Rapid Test Acceptance
The relevance of this research to public health is to make it possible to test for hepatitis C and syphilis at point of care so that people will receive their results immediately instead of requiring people to wait for at least a…
- Conditions
- HIV, Hepatitis C, Hepatitis B, Syphilis
- Trial name
- BSARTA (NCT01317784)
- Testing
- Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- California State University, Long Beach
Hepatitis C
Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations
The major goal of this project is to identify the role of the immune responses in the emergence of protease inhibitor mutants during therapy.
- Trial name
- NCT01517529
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Cincinnati
Hepatitis C, Chronic, Hepacivirus
Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)
Patients receiving a patient assistance program during therapy for Hepatitis C will be enrolled into this study. All patients will receive PegIntron pen and Rebetol according to label and the patient assistance program.
- Trial name
- NCT00704522
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908), Patient assistance program
- Volunteers
- 601 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for…
- Trial name
- ETHOS II (NCT03685045)
- Testing
- Campaign days
- Where
- 32 sites in Australia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Hepatitis C, Chronic
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)
This is an open-label, randomized, comparative, multicenter, 48-week study designed to evaluate the efficacy and safety of combination treatment with pegylated interferon and ribavirin in adult subjects with a diagnosis of…
- Trial name
- NCT00202839
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Ribavirin
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection, Hepatitis C Infection
Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam
With the advent of direct acting antiviral (DAA) treatment in 2013, HCV elimination has become feasible. Still, achieving HCV elimination in resource-limited countries appears to be arduous as several challenges need to be…
- Trial name
- MOVIDA-Hep2 (NCT05506475)
- Testing
- Blood samples
- Where
- 2 sites in Vietnam
- Volunteers
- 400 people
- Sponsor
- Institut Pasteur
HEPATITIS C (HCV)
Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive Housing
The objective of this study is to extend our prior research by conducting a pragmatic implementation trial using a parallel-group, cluster randomized design to evaluate the PPP-CCM's ability to improve access to DAAs for HCV…
- Trial name
- HepP3 (NCT07667101)
- Testing
- PPP-CCM
- Where
- United States
- Volunteers
- 444 people
- Sponsor
- University of Washington
Hepatitis C, Liver Transplantation
Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients
This is an exploratory study to evaluate the impact of eliminating steroid administration upon viral HCV load at 12 months measured by quantitative serum HCV-RNA determination in patients transplanted for HCV cirrhosis.
- Trial name
- CHASE (NCT00295607)
- Testing
- Tacrolimus, steroids, monoclonal anti-IL2R antibody
- Where
- 17 sites in Czechia, France and 6 more
- Volunteers
- 138 people
- Sponsor
- Astellas Pharma Inc
HIV Infection, HBV Infection
"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
The VIROPREG study is a French prospective multicenter cohort study that aims to assess the impact of viral infections and antiviral treatments received during pregnancy on maternal and child health.
- Conditions
- HIV Infection, HBV Infection, HDV Infection, HCV Infection
- Trial name
- VIROPREG (NCT07412977)
- Testing
- Blood sampling, Umbilical cord blood sampling, Survey using a questionnaire
- Where
- France
- Volunteers
- 5,160 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Cirrhosis
Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
This is a randomized, open label, single center safety and efficacy study. At least 40 cirrhotic subjects with HCV genotype 3 will receive standard of care treatment of sofosbuvir and ribavirin (SOF/RBV) as well as 60 mg daily of…
- Trial name
- NCT02304159
- Testing
- daclatasvir, Sofosbuvir, Sovaldi, Ribavirin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Hepatitis C
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.
- Trial name
- NCT02673489
- Testing
- DCV, SOF, RBV
- Where
- 19 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
HIV/AIDS, Hepatitis C
Study of HIV, HCV, APS and Phylogenetics for PWID
This study will determine whether assisted partner notification services (APS) can identify and link to care, the sexual and needle-sharing partners of HIV-infected and HIV/hepatitis C (HCV) co-infected persons who inject drugs…
- Trial name
- SHARP (NCT03447210)
- Testing
- Assisted Partner Services
- Where
- 3 sites in Kenya
- Volunteers
- 4,301 people
- Sponsor
- University of Washington
HIV, HIV Infections
Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients
The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to tenofovir on virologic suppression.
- Trial name
- NCT00358696
- Testing
- tenofovir
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Chronic Hepatitis C Infection
Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy
Prospective, longitudinal multi-center study performed in 15 participating substitution centers in Germany. Aims: Primary objective: To compare the impact of the different substitution drugs (methadone, buprenorphine, and…
- Trial name
- NCT00682591
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- University of Wuerzburg
Chronic Hepatitis C
Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders
For chronic hepatitis C patients unresponsive to previous (PEG-)IFN/RBV combination therapy we propose continuous subcutaneous administration of high-dose IFN-a2b (Intron A®) for 48 weeks in combination with 15 mg/kg/day RBV…
- Trial name
- SCIN-C (NCT00624325)
- Testing
- interferon alfa-2b
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Foundation for Liver Research
Hepatitis C Virus (HCV) Infection
Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)
The purpose of this study was to evaluate the efficacy of 8 and 12 weeks of treatment with a fixed dose combination (FDC) of elbasvir (EBR) 50 mg + grazoprevir (GZR) 100 mg (i.e., MK-5172A) as assessed by the percentage of…
- Trial name
- NCT03111108
- Testing
- EBR/GZR (50 mg/100 mg) FDC
- Where
- 13 sites in France
- Volunteers
- 117 people
- Sponsor
- Merck Sharp & Dohme LLC
HCV
Safety of Sofosbuvir ,Daclatasvir in HCV Patients and RAVS in Resistent and Relapsed Cases
To identify side effects of Sofosbuvir/ Daclatasvir treatment regimen of chronic HCV GT-4 infection. To assess the occurrence and the prevalence of RAVs in patients with treatment failure and relapse after sofosbuvir and…
- Trial name
- RAVs (NCT03572140)
- Testing
- RAVS In relapsed and resistent cases
- Volunteers
- 297 people
- Sponsor
- Assiut University
Hepatitis C,Chronic Children, Only
Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years
Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the world map of HCV. Results in adults are promising. FDA approved only two drugs in the pediatric age group 12 to 17 years.
- Trial name
- NCT07905989
- Testing
- Sofosbuvir/Daclatasvir
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- National Liver Institute, Egypt
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
The primary objective of the PK Lead-in Phase of the study is to evaluate the steady state pharmacokinetics (PK) and confirm the dose of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) in hepatitis C virus…
- Trial name
- NCT02249182
- Testing
- LDV/SOF, RBV
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 226 people
- Sponsor
- Gilead Sciences
Hepatitis C
Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
The purpose of this study is to evaluate the safety and pharmacokinetics of MK-1075, and to determine the ability of MK-1075 to reduce HCV viral load, following administration of a single dose in HCV-infected participants.
- Trial name
- NCT02392494
- Testing
- MK-1075
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.